Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NextCure, Inc. (NXTC)
USD6.63
+0.05 (+0.76%)
US NASDAQ Healthcare Biotechnology
Address
9000 Virginia Manor Road 20705
Beltsville, MD, US
Beltsville, MD, US
CEO
Michael S. Richman
Website
nextcure.com
IPO
2019-05-09
CIK 1661059 ISIN US65343E2072
Description
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
News Sentiment (7d)
Based on only 1 article — low confidence
- 3 Cancer Stocks to Watch as Oncology Innovation Accelerates Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.63
+0.05 (+0.76%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
100.5K
Beta
1.30
Float Shares
1.60M
Free Float %
59.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.20% | -8.26% | -15.98% | -26.13% | +5.27% | -31.08% | +87.72% | -52.62% | -89.81% | -95.90% | -95.90% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
6.63
Low
15.00
+126.2%
Consensus
15.00
+126.2%
Median
15.00
+126.2%
High
15.00
+126.2%
DCF (Unlevered)
7.07
+6.6%
DCF (Levered)
7.68
+15.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
15.00
+126.2%
|
| All Time | 3 |
8.00
+20.7%
|
Quality scores
Altman Z-Score
-19.10
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+17.7% Q1'26: +60.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -4,744.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+22.0% Q1'26: +124.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q1'26: -0.10× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.35M
est: 5.05M (+25.8%)
|
22.38M
est: 22.34M (+0.2%)
|
—
|
—
|
3.30M
3.30M – 3.30M
|
7.00M
7.00M – 7.00M
+112.1% YoY
|
10.30M
10.30M – 10.30M
+47.1% YoY
|
22.60M
22.60M – 22.60M
+119.4% YoY
|
39.70M
39.70M – 39.70M
+75.7% YoY
|
| EBITDA |
-34.79M
est: 3.03M (-1,249.5%)
|
-37.81M
est: 13.40M (-382.1%)
|
-54.34M
|
-55.43M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-37.48M
est: 3.03M (-1,338.3%)
|
-41.23M
est: 13.40M (-407.5%)
|
-57.21M
|
-57.62M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-33.74M
est: -56.77M (+40.6%)
|
-36.60M
est: -37.44M (+2.2%)
|
-55.65M
est: -53.96M (-3.1%)
|
-55.84M
est: -55.84M (+0.0%)
|
-22.48M
-24.81M – -20.15M
+59.7% YoY
|
-27.78M
-33.26M – -22.31M
-23.6% YoY
|
-9.49M
-9.49M – -9.49M
+65.8% YoY
|
-6.51M
-6.51M – -6.51M
+31.4% YoY
|
-625.3K
-625.3K – -625.3K
+90.4% YoY
|
| SGA |
9.61M
est: 4.80M (+100.1%)
|
17.05M
est: 21.28M (-19.9%)
|
15.72M
|
12.69M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-25.79
est: -24.36 (-5.9%)
|
-15.95
est: -16.07 (+0.7%)
|
-23.88
est: -23.28 (-2.6%)
|
-19.65
est: -17.63 (-11.5%)
|
-7.91
-8.73 – -7.09
+55.1% YoY
|
-9.78
-11.70 – -7.85
-23.6% YoY
|
-3.34
-3.34 – -3.34
+65.8% YoY
|
-2.29
-2.29 – -2.29
+31.4% YoY
|
-0.22
-0.22 – -0.22
+90.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-49.98M
OE per share TTM
-16.63
Owner's Yield
-93.71%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
302.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
24
Total invested
26.93M
Insider transactions (90d)
0
Beneficial owners (>5%)
35
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Advisors LLC | 2.71M | 8.40% | — | 2.71M | — | 10.00 | IA | Delaware | 2019-05-21 | ↗ |
| 2 | OrbiMed Capital GP VI LLC | 2.71M | 8.40% | — | 2.71M | — | 10.00 | OO | Delaware | 2019-05-21 | ↗ |
| 3 | Arsani William | 2.50M | 11.00% | — | 2.50M | — | 2.50M | HC, IN | United States | 2024-11-14 | ↗ |
| 4 | Logos GP LLC | 2.50M | 11.00% | — | 2.50M | — | 2.50M | OO | Delaware | 2024-11-14 | ↗ |
| 5 | Logos Global Management GP LLC | 2.50M | 11.00% | — | 2.50M | — | 2.50M | HC, OO | Delaware | 2024-11-14 | ↗ |
| 6 | Logos Global Management LP | 2.50M | 11.00% | — | 2.50M | — | 2.50M | IA, PN | Delaware | 2024-11-14 | ↗ |
| 7 | Logos Global Master Fund LP | 2.50M | 11.00% | — | 2.50M | — | 2.50M | PN | Cayman Islands | 2024-11-14 | ↗ |
| 8 | 10. | 2.25M | 8.20% | 2.25M | — | 2.25M | — | OO | Cayman Islands | 2020-02-06 | ↗ |
| 9 | Yi Shi | 1.70M | 6.20% | — | 1.70M | — | 1.70M | IN | United States | 2022-02-09 | ↗ |
| 10 | S | 1.67M | 5.98% | — | 1.67M | — | 1.67M | IA | Delaware | 2024-06-27 | ↗ |
| 11 | ( 82-5524518 | 1.64M | 7.20% | — | 1.64M | — | — | OO | Delaware | 2019-05-22 | ↗ |
| 12 | Israel A. Englander | 1.45M | 5.20% | — | 1.45M | — | 1.45M | IN | — | 2023-01-24 | ↗ |
| 13 | Millennium Group Management LLC | 1.45M | 5.20% | — | 1.45M | — | 1.45M | OO | — | 2023-01-24 | ↗ |
| 14 | Millennium Management LLC | 1.45M | 5.20% | — | 1.45M | — | 1.45M | OO | — | 2023-01-24 | ↗ |
| 15 | Dr. Jeffrey R. Jay, M.D. | 1.38M | 5.00% | — | 1.38M | — | — | HC, IN | USA | 2020-02-21 | ↗ |
| 16 | Great Point Partners, LLC | 1.38M | 5.00% | — | 1.38M | — | — | IA, OO | USA | 2020-02-21 | ↗ |
| 17 | Mr. David Kroin | 1.38M | 5.00% | — | 1.38M | — | — | HC, IN | USA | 2020-02-21 | ↗ |
| 18 | Shi | 1.21M | 7.80% | — | 2.09M | — | 2.09M | IN | States | 2020-02-13 | ↗ |
| 19 | (1) BlackRock, Inc. | 1.20M | 3.20% | 1.11M | — | 1.20M | — | HC | Delaware | 2021-07-12 | ↗ |
| 20 | Bihua Chen | 1.20M | 5.27% | — | 1.20M | — | — | IN | Cayman Islands | 2019-11-18 | ↗ |
| 21 | Cormorant Asset Management, LP | 1.20M | 5.27% | — | 1.20M | — | — | PN | Cayman Islands | 2019-11-18 | ↗ |
| 22 | Biosciences Fund III, L.P. (“BIOIII”) | 1.14M | 4.20% | 1.14M | 1.14M | 1.14M | 1.14M | PN | Islands | 2020-02-13 | ↗ |
| 23 | LAV Biosciences Fund III, L.P. (“BIOIII”) | 1.14M | 4.10% | 1.14M | 1.14M | 1.14M | 1.14M | PN | Cayman Islands | 2022-02-09 | ↗ |
| 24 | Cormorant Global Healthcare GP, LLC | 1.13M | 4.95% | — | 1.13M | — | — | OO | Cayman Islands | 2019-11-18 | ↗ |
| 25 | Cormorant Global Healthcare Master Fund, LP | 1.13M | 4.95% | — | 1.13M | — | — | PN | Cayman Islands | 2019-11-18 | ↗ |
| 26 | Asia Ventures Fund III, L.P. (“FUNDIII”) | 568.1K | 2.10% | 568.1K | 568.1K | 568.1K | 568.1K | PN | Islands | 2020-02-13 | ↗ |
| 27 | Lilly Asia Ventures Fund III, L.P. (“FUNDIII”) | 568.1K | 2.10% | 568.1K | 568.1K | 568.1K | 568.1K | PN | Cayman Islands | 2022-02-09 | ↗ |
| 28 | Morgan Stanley | 399.9K | 1.40% | — | 373.9K | — | 399.9K | HC, CO | Delaware. | 2021-05-10 | ↗ |
| 29 | Morgan Stanley Capital Services LLC | 372.8K | 1.40% | — | 372.8K | — | 372.8K | CO | Delaware. | 2021-05-10 | ↗ |
| 30 | Biosciences Fund V sub A, L.P. (“FUNDVSUBA”) | 274.6K | 1.00% | 274.6K | 274.6K | 274.6K | 274.6K | PN | States | 2020-02-13 | ↗ |
| 31 | Opportunity Limited (“LAVO”) | 109.8K | 0.40% | 109.8K | 109.8K | 109.8K | 109.8K | OO | Virgin Islands | 2020-02-13 | ↗ |
| 32 | 2. | 10.00 | 4.90% | — | 1.12M | — | — | HC, PN | Delaware | 2019-05-17 | ↗ |
| 33 | LAV Biosciences Fund V sub A, L.P. (“FUNDVSUBA”) | — | 0.00% | — | — | — | — | PN | United States | 2022-02-09 | ↗ |
| 34 | LAV Opportunity Limited (“LAVO”) | — | 0.00% | — | — | — | — | OO | British Virgin Islands | 2022-02-09 | ↗ |
| 35 | Lord, Abbett & Co. LLC | — | 0.00% | — | — | — | — | IA | Delaware | 2021-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
24
+7 vs prev Q
New positions
9
Closed positions
2
Increased
14
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BARCLAYS PLC | — -67.5K (-100.0%) | — -92.5K (-100.0%) | 0.00% -2.843 pp | 0.00% +0.000 pp | USD— | 27 qtrs SOLD |
| 2 | CARDIFF PARK ADVISORS, LLC | — -21.8K (-100.0%) | — -127.9K (-100.0%) | 0.00% -0.919 pp | 0.00% -0.010 pp | USD— | 8 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 15 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.00% | 19.4K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 203.4K | 0.05% |
| 3 | Dimensional - US Core Equity 1 ETF DCOR | 0.00% | 1.7K | 0.14% |
| 4 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.6K | 0.03% |
| 5 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 4.4K | 0.17% |
| 6 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 328.55 | 0.17% |
| 7 | Vanguard Total Stock Market ETF VTI | 0.00% | 760.2K | 0.03% |
| 8 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 1.3K | 0.43% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.7K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 906.75 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
121.6K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+121,550
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-30 | Shaw Kevin G. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 8,270 | 10.85 | 89.7K | 8,270 | D | ↗ |
| 2026-01-30 | Richman Michael | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 38,190 | 10.85 | 414.4K | 38,190 | D | ↗ |
| 2026-01-30 | Mayer Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 14,670 | 10.85 | 159.2K | 14,670 | D | ↗ |
| 2026-01-30 | Kundu Sourav | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 8,270 | 10.85 | 89.7K | 8,270 | D | ↗ |
| 2026-01-30 | Guha Udayan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 14,670 | 10.85 | 159.2K | 14,670 | D | ↗ |
| 2026-01-30 | Cobourn Steven P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 14,670 | 10.85 | 159.2K | 14,670 | D | ↗ |
| 2025-06-20 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 18,700 | 0.47 | 8.8K | 18,700 | D | ↗ |
| 2025-06-20 | Simcere Zaiming, Inc. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 338,636 | I | ↗ |
| 2025-06-20 | KABAKOFF DAVID S | Director | A-Award | A | Stock Option (Right to Buy) | 28,050 | 0.47 | 13.2K | 28,050 | D | ↗ |
| 2025-06-20 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 18,700 | 0.47 | 8.8K | 18,700 | D | ↗ |
| 2025-06-20 | Houston John G | Director | A-Award | A | Stock Option (Right to Buy) | 18,700 | 0.47 | 8.8K | 18,700 | D | ↗ |
| 2025-06-20 | Feigal Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 18,700 | 0.47 | 8.8K | 18,700 | D | ↗ |
| 2025-06-20 | Borgman Anne Elizabeth | Director | A-Award | A | Stock Option (Right to Buy) | 18,700 | 0.47 | 8.8K | 18,700 | D | ↗ |
| 2025-02-01 | Guha Udayan | Officer | — | — | Employee Stock Option (Right to Buy) | 66,125 | 1.22 | 80.7K | 0 | D | ↗ |
| 2025-01-31 | Shaw Kevin G. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 66,125 | 0.80 | 53.2K | 66,125 | D | ↗ |
| 2025-01-31 | Richman Michael | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 305,500 | 0.80 | 245.9K | 305,500 | D | ↗ |
| 2025-01-31 | Mayer Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 117,375 | 0.80 | 94.5K | 117,375 | D | ↗ |
| 2025-01-31 | Langermann Sol | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 117,375 | 0.80 | 94.5K | 117,375 | D | ↗ |
| 2025-01-31 | Kundu Sourav | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 66,125 | 0.80 | 53.2K | 66,125 | D | ↗ |
| 2025-01-31 | Cobourn Steven P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 117,375 | 0.80 | 94.5K | 117,375 | D | ↗ |
| 2024-06-20 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 18,700 | 1.50 | 28.1K | 18,700 | — | ↗ |
| 2024-06-20 | KABAKOFF DAVID S | Director | A-Award | A | Stock Option (Right to Buy) | 28,050 | 1.50 | 42.1K | 28,050 | — | ↗ |
| 2024-06-20 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 18,700 | 1.50 | 28.1K | 18,700 | — | ↗ |
| 2024-06-20 | Houston John G | Director | A-Award | A | Stock Option (Right to Buy) | 18,700 | 1.50 | 28.1K | 18,700 | — | ↗ |
| 2024-06-20 | Feigal Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 18,700 | 1.50 | 28.1K | 18,700 | — | ↗ |
| 2024-06-20 | Borgman Anne Elizabeth | Director | A-Award | A | Stock Option (Right to Buy) | 18,700 | 1.50 | 28.1K | 18,700 | — | ↗ |
| 2024-03-29 | Shaw Kevin G. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 93,900 | 2.23 | 209.4K | 93,900 | — | ↗ |
| 2024-03-29 | Richman Michael | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 244,400 | 2.23 | 545.0K | 244,400 | — | ↗ |
| 2024-03-29 | Myint Han | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 93,900 | 2.23 | 209.4K | 93,900 | — | ↗ |
| 2024-03-29 | Mayer Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 93,900 | 2.23 | 209.4K | 93,900 | — | ↗ |
| 2024-03-29 | Langermann Sol | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 93,900 | 2.23 | 209.4K | 93,900 | — | ↗ |
| 2024-03-29 | Kundu Sourav | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 52,900 | 2.23 | 118.0K | 52,900 | — | ↗ |
| 2024-03-29 | Cobourn Steven P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 93,900 | 2.23 | 209.4K | 93,900 | — | ↗ |
| 2024-01-31 | Shaw Kevin G. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 66,125 | 1.22 | 80.7K | 66,125 | — | ↗ |
| 2024-01-31 | Richman Michael | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 305,500 | 1.22 | 372.7K | 305,500 | — | ↗ |
| 2024-01-31 | Myint Han | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 117,375 | 1.22 | 143.2K | 117,375 | — | ↗ |
| 2024-01-31 | Mayer Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 117,375 | 1.22 | 143.2K | 117,375 | — | ↗ |
| 2024-01-31 | Langermann Sol | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 117,375 | 1.22 | 143.2K | 117,375 | — | ↗ |
| 2024-01-31 | Kundu Sourav | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 66,125 | 1.22 | 80.7K | 66,125 | — | ↗ |
| 2024-01-31 | Cobourn Steven P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 117,375 | 1.22 | 143.2K | 117,375 | — | ↗ |
| 2023-06-22 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 1.62 | 23.1K | 14,250 | — | ↗ |
| 2023-06-22 | Nicholson Garry A | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 1.62 | 23.1K | 14,250 | — | ↗ |
| 2023-06-22 | Khuong Chau Quang | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 1.62 | 23.1K | 14,250 | — | ↗ |
| 2023-06-22 | KABAKOFF DAVID S | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 1.62 | 23.1K | 14,250 | — | ↗ |
| 2023-06-22 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 1.62 | 23.1K | 14,250 | — | ↗ |
| 2023-06-22 | Houston John G | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 1.62 | 23.1K | 14,250 | — | ↗ |
| 2023-06-22 | Feigal Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 1.62 | 23.1K | 14,250 | — | ↗ |
| 2023-06-22 | Borgman Anne Elizabeth | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 1.62 | 23.1K | 14,250 | — | ↗ |
| 2023-02-28 | Shaw Kevin G. | — | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 1.55 | 116.3K | 75,000 | — | ↗ |
| 2023-02-28 | Richman Michael | — | A-Award | A | Employee Stock Option (Right to Buy) | 309,000 | 1.55 | 479.0K | 309,000 | — | ↗ |
| 2023-02-28 | Myint Han | — | A-Award | A | Employee Stock Option (Right to Buy) | 135,000 | 1.55 | 209.3K | 135,000 | — | ↗ |
| 2023-02-28 | Mayer Timothy | — | A-Award | A | Employee Stock Option (Right to Buy) | 135,000 | 1.55 | 209.3K | 135,000 | — | ↗ |
| 2023-02-28 | Langermann Sol | — | A-Award | A | Employee Stock Option (Right to Buy) | 135,000 | 1.55 | 209.3K | 135,000 | — | ↗ |
| 2023-02-28 | Kundu Sourav | — | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 1.55 | 116.3K | 75,000 | — | ↗ |
| 2023-02-28 | Cobourn Steven P. | — | A-Award | A | Employee Stock Option (Right to Buy) | 135,000 | 1.55 | 209.3K | 135,000 | — | ↗ |
| 2023-02-24 | Shaw Kevin G. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-23 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 4.77 | 68.0K | 14,250 | — | ↗ |
| 2022-06-23 | Nicholson Garry A | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 0.00 | — | 14,250 | — | ↗ |
| 2022-06-23 | Khuong Chau Quang | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 4.77 | 68.0K | 14,250 | — | ↗ |
| 2022-06-23 | KABAKOFF DAVID S | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 0.00 | — | 14,250 | — | ↗ |
| 2022-06-23 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 4.77 | 68.0K | 14,250 | — | ↗ |
| 2022-06-23 | Houston John G | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 4.77 | 68.0K | 14,250 | — | ↗ |
| 2022-06-23 | Feigal Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 0.00 | — | 14,250 | — | ↗ |
| 2022-06-23 | Borgman Anne Elizabeth | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 0.00 | — | 14,250 | — | ↗ |
| 2022-01-31 | Richman Michael | — | A-Award | A | Employee Stock Option (Right to Buy) | 262,400 | 5.57 | 1.46M | 262,400 | — | ↗ |
| 2022-01-31 | Myint Han | — | A-Award | A | Employee Stock Option (Right to Buy) | 103,600 | 5.57 | 577.1K | 103,600 | — | ↗ |
| 2022-01-31 | Mayer Timothy | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 131,200 | 5.57 | 730.8K | 131,200 | — | ↗ |
| 2022-01-31 | Liu Linda | — | A-Award | A | Employee Stock Option (Right to Buy) | 65,600 | 5.57 | 365.4K | 65,600 | — | ↗ |
| 2022-01-31 | Langermann Sol | — | A-Award | A | Employee Stock Option (Right to Buy) | 117,400 | 5.57 | 653.9K | 117,400 | — | ↗ |
| 2022-01-31 | Kundu Sourav | — | A-Award | A | Employee Stock Option (Right to Buy) | 58,700 | 5.57 | 327.0K | 58,700 | — | ↗ |
| 2022-01-31 | Cobourn Steven P. | — | A-Award | A | Employee Stock Option (Right to Buy) | 96,700 | 5.57 | 538.6K | 96,700 | — | ↗ |
| 2021-10-01 | Feigal Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 10,384 | 7.56 | 78.5K | 10,384 | — | ↗ |
| 2021-10-01 | Borgman Anne Elizabeth | Director | A-Award | A | Stock Option (Right to Buy) | 28,500 | 7.56 | 215.5K | 28,500 | — | ↗ |
| 2021-07-15 | Kundu Sourav | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 7.89 | 1.18M | 150,000 | — | ↗ |
| 2021-07-05 | Kundu Sourav | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-24 | Xu Stella | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 8.21 | 117.0K | 14,250 | — | ↗ |
| 2021-06-24 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 8.21 | 117.0K | 14,250 | — | ↗ |
| 2021-06-24 | Nicholson Garry A | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 8.21 | 117.0K | 14,250 | — | ↗ |
| 2021-06-24 | Khuong Chau Quang | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 8.21 | 117.0K | 14,250 | — | ↗ |
| 2021-06-24 | KABAKOFF DAVID S | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 8.21 | 117.0K | 14,250 | — | ↗ |
| 2021-06-24 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 8.21 | 117.0K | 14,250 | — | ↗ |
| 2021-06-24 | Houston John G | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 8.21 | 117.0K | 14,250 | — | ↗ |
| 2021-03-15 | Richman Michael | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 300,000 | 12.59 | 3.78M | 300,000 | — | ↗ |
| 2021-03-15 | Mayer Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 12.59 | 1.26M | 100,000 | — | ↗ |
| 2021-03-15 | Liu Linda | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 12.59 | 1.26M | 100,000 | — | ↗ |
| 2021-03-15 | Langermann Sol | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 12.59 | 1.26M | 100,000 | — | ↗ |
| 2021-03-15 | Cobourn Steven P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 12.59 | 1.26M | 100,000 | — | ↗ |
| 2021-01-13 | Myint Han | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 12.09 | 2.42M | 200,000 | — | ↗ |
| 2021-01-11 | Myint Han | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-09-10 | Houston John G | Director | A-Award | A | Stock Option (Right to Buy) | 28,500 | 9.14 | 260.5K | 28,500 | — | ↗ |
| 2020-07-14 | Heller Kevin N. | Officer | M-Exempt | A | Common Stock | 27,229 | 1.77 | 48.2K | 49,011 | — | ↗ |
| 2020-06-11 | Xu Stella | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 24.13 | 343.9K | 14,250 | — | ↗ |
| 2020-06-11 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 24.13 | 343.9K | 14,250 | — | ↗ |
| 2020-06-11 | Nicholson Garry A | Director | A-Award | A | Stock Option (Right to Buy) | 16,083 | 24.13 | 388.1K | 16,083 | — | ↗ |
| 2020-06-11 | Morrison Briggs | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 24.13 | 343.9K | 14,250 | — | ↗ |
| 2020-06-11 | Li Judith | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 24.13 | 343.9K | 14,250 | — | ↗ |
| 2020-06-11 | Khuong Chau Quang | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 24.13 | 343.9K | 14,250 | — | ↗ |
| 2020-06-11 | KABAKOFF DAVID S | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 24.13 | 343.9K | 14,250 | — | ↗ |
| 2020-06-11 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 14,250 | 24.13 | 343.9K | 14,250 | — | ↗ |
| 2020-03-25 | Nicholson Garry A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-28 | Richman Michael | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 225,000 | 41.76 | 9.40M | 225,000 | — | ↗ |
| 2020-02-28 | Mayer Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 78,200 | 41.76 | 3.27M | 78,200 | — | ↗ |
| 2020-02-28 | Liu Linda | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 39,100 | 41.76 | 1.63M | 39,100 | — | ↗ |
| 2020-02-28 | Langermann Sol | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 78,200 | 41.76 | 3.27M | 78,200 | — | ↗ |
| 2020-02-28 | Heller Kevin N. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,050 | 41.76 | 4.18M | 100,050 | — | ↗ |
| 2020-02-28 | Cobourn Steven P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 78,200 | 41.76 | 3.27M | 78,200 | — | ↗ |
| 2020-02-28 | Bingham James B. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 78,200 | 41.76 | 3.27M | 78,200 | — | ↗ |
| 2019-11-27 | Liu Linda | Officer | M-Exempt | A | Common Stock | 20,745 | 1.21 | 25.1K | 55,234 | — | ↗ |
| 2019-11-15 | Sofinnova Venture Partners IX, L.P. | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 36.75 | 5.51M | 2,671,856 | — | ↗ |
| 2019-06-13 | Xu Stella | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 15.57 | 342.5K | 22,000 | — | ↗ |
| 2019-06-13 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 15.57 | 342.5K | 22,000 | — | ↗ |
| 2019-06-13 | SHANNON TIMOTHY M | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 15.57 | 342.5K | 22,000 | — | ↗ |
| 2019-06-13 | Morrison Briggs | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 15.57 | 342.5K | 22,000 | — | ↗ |
| 2019-06-13 | Li Judith | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 15.57 | 342.5K | 22,000 | — | ↗ |
| 2019-06-13 | Khuong Chau Quang | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 15.57 | 342.5K | 22,000 | — | ↗ |
| 2019-06-13 | KABAKOFF DAVID S | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 15.57 | 342.5K | 22,000 | — | ↗ |
| 2019-06-13 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 15.57 | 342.5K | 22,000 | — | ↗ |
| 2019-05-13 | Xu Stella | Director | C-Conversion | D | Series B-2 Preferred Stock | 7,861,636 | 0.00 | — | 0 | — | ↗ |
| 2019-05-13 | Sofinnova Venture Partners IX, L.P. | 10% Owner | C-Conversion | A | Common Stock | 469,713 | 0.00 | — | 2,121,856 | — | ↗ |
| 2019-05-13 | SHANNON TIMOTHY M | Director | C-Conversion | D | Series A-1 Preferred Stock | 3,582,000 | 0.00 | — | 0 | — | ↗ |
| 2019-05-13 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 350,000 | 15.00 | 5.25M | 2,711,013 | — | ↗ |
| 2019-05-13 | Khuong Chau Quang | Director | C-Conversion | D | Series A-2 Preferred Stock | 5,970,000 | 0.00 | — | 0 | — | ↗ |
| 2019-05-13 | CANAAN X L.P. | 10% Owner | C-Conversion | A | Common Stock | 743,110 | 0.00 | — | 1,188,976 | — | ↗ |
| 2019-05-13 | Alexandria Venture Investments, LLC | 10% Owner | C-Conversion | D | Series A-3 Preferred Stock | 365,727 | 0.00 | — | 0 | — | ↗ |
| 2019-05-08 | Xu Stella | Director / 10% Owner | — | I | Series B-2 Preferred Stock | 978,570 | 0.00 | — | 0 | — | ↗ |
| 2019-05-08 | Webster Stephen W | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-08 | Sofinnova Venture Partners IX, L.P. | 10% Owner | — | D | Series B-1 Preferred Stock | 469,713 | 0.00 | — | 0 | — | ↗ |
| 2019-05-08 | SHANNON TIMOTHY M | Director | — | I | Series A-3 Preferred Stock | 729,599 | 0.00 | — | 0 | — | ↗ |
| 2019-05-08 | Richman Michael | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 385,869 | — | ↗ |
| 2019-05-08 | ORBIMED ADVISORS LLC | Director / 10% Owner | — | I | Series A-2 Preferred Stock | 743,110 | 0.00 | — | 0 | — | ↗ |
| 2019-05-08 | Morrison Briggs | Director | — | D | Employee Stock Option (Right to Buy) | 7,468 | 1.21 | 9.0K | 0 | — | ↗ |
| 2019-05-08 | Liu Linda | Officer | — | D | Employee Stock Option (Right to Buy) | 31,118 | 1.21 | 37.7K | 0 | — | ↗ |
| 2019-05-08 | Li Judith | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-08 | Langermann Sol | Officer | — | D | Common Stock | 0 | 0.00 | — | 37,342 | — | ↗ |
| 2019-05-08 | Khuong Chau Quang | Director | — | I | Series A-2 Preferred Stock | 743,110 | 0.00 | — | 0 | — | ↗ |
| 2019-05-08 | KABAKOFF DAVID S | Director | — | D | Employee Stock Option (Right to Buy) | 37,342 | 7.63 | 284.9K | 0 | — | ↗ |
| 2019-05-08 | Jones Elaine V | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-08 | Heller Kevin N. | Officer | — | D | Common Stock | 0 | 0.00 | — | 21,782 | — | ↗ |
| 2019-05-08 | Cobourn Steven P. | Officer | — | D | Employee Stock Option (Right to Buy) | 74,684 | 1.77 | 132.2K | 0 | — | ↗ |
| 2019-05-08 | CANAAN X L.P. | 10% Owner | — | D | Series A-3 Preferred Stock | 729,599 | 0.00 | — | 0 | — | ↗ |
| 2019-05-08 | Bingham James B. | Officer | — | D | Employee Stock Option (Right to Buy) | 18,671 | 1.21 | 22.6K | 0 | — | ↗ |
| 2019-05-08 | Alexandria Venture Investments, LLC | 10% Owner | — | D | Series A-2 Preferred Stock | 46,366 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
2.68M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael Richman President and Chief Executive Officer | 609.3K | — | — | 189.2K | 122.0K | 21.3K | 941.7K | 20.09% | ↗ |
| 2 | 2025 | Udayan Guha, M.D., Ph.D. Chief Medical Officer | 474.2K | — | — | 72.7K | 76.2K | 16.2K | 639.2K | 11.37% | ↗ |
| 3 | 2025 | Timothy Mayer, Ph.D. Chief Operating Officer | 468.4K | — | — | 72.7K | 75.1K | 17.0K | 633.2K | 11.48% | ↗ |
| 4 | 2024 | Michael Richman President and Chief Executive Officer | 591.5K | — | — | 658.2K | 240.5K | 20.7K | 1.51M | 43.56% | ↗ |
| 5 | 2024 | Solomon Langermann, Ph.D. Chief Scientific Officer | 463.3K | — | — | 252.9K | 150.8K | 15.8K | 882.8K | 28.65% | ↗ |
| 6 | 2024 | Han Myint, M.D., FACP former Chief Medical Officer | 240.3K | — | — | 252.9K | — | 381.1K | 874.3K | 28.93% | ↗ |
| 7 | 2024 | Timothy Mayer, Ph.D. Chief Operating Officer | 454.7K | — | — | 252.9K | 148.0K | 16.6K | 872.2K | 29.00% | ↗ |
| 8 | 2023 | Michael Richman President and Chief Executive Officer | 571.9K | — | — | 346.2K | 106.4K | 20.1K | 1.04M | 33.14% | ↗ |
| 9 | 2023 | Han Myint, M.D., FACP Chief Medical Officer | 462.0K | — | — | 151.3K | 68.8K | 15.9K | 697.9K | 21.67% | ↗ |
| 10 | 2023 | Han Myint, M.D., FACP former Chief Medical Officer | 462.0K | — | — | 151.3K | 68.8K | 15.9K | 697.9K | 21.67% | ↗ |
| 11 | 2023 | Sol Langerman. Ph.D. Chief Scientific Officer | 448.2K | — | — | 151.3K | 66.7K | 15.4K | 681.6K | 22.19% | ↗ |
| 12 | 2023 | Solomon Langermann, Ph.D. Chief Scientific Officer | 448.2K | — | — | 151.3K | 66.7K | 15.4K | 681.6K | 22.19% | ↗ |
| 13 | 2022 | Michael Richman President and Chief Executive Officer | 549.4K | — | — | 1.01M | 151.3K | 13.3K | 1.72M | 58.59% | ↗ |
| 14 | 2022 | Sol Langermann, Ph.D. Chief Scientific Officer | 432.2K | — | — | 451.9K | 95.3K | 11.1K | 990.5K | 45.62% | ↗ |
| 15 | 2022 | Sol Langerman. Ph.D. Chief Scientific Officer | 432.2K | — | — | 451.9K | 95.3K | 11.1K | 990.5K | 45.62% | ↗ |
| 16 | 2022 | Han Myint, M.D., FACP Chief Medical Officer | 445.4K | — | — | 398.9K | 98.2K | 10.8K | 953.3K | 41.84% | ↗ |
| 17 | 2021 | Michael Richman President and Chief Executive Officer | 529.2K | — | — | 2.60M | 194.3K | 3.0K | 3.32M | 78.13% | ↗ |
| 18 | 2021 | Han Myint, M.D., FACP Chief Medical Officer | 415.3K | 75.0K | — | 1.65M | 119.6K | 2.0K | 2.26M | 72.94% | ↗ |
| 19 | 2021 | Sol Langermann, Ph.D. Chief Scientific Officer | 406.4K | — | — | 865.0K | 119.7K | 1.9K | 1.39M | 62.10% | ↗ |
| 20 | 2020 | Michael Richman President and Chief Executive Officer | 491.0K | — | — | 5.84M | 150.0K | 3.0K | 6.49M | 90.08% | ↗ |
| 21 | 2020 | Kevin Heller, M.D. Former Chief Medical Officer | 237.7K | — | — | 2.60M | — | 1.9K | 2.84M | 91.56% | ↗ |
| 22 | 2020 | Sol Langermann Chief Scientific Officer | 372.7K | — | — | 2.03M | 78.8K | 1.9K | 2.48M | 81.75% | ↗ |
| 23 | 2020 | Sol Langermann, Ph.D. Chief Scientific Officer | 372.7K | — | — | 2.03M | 78.8K | 1.9K | 2.48M | 81.75% | ↗ |
| 24 | 2020 | James B. Bingham, Ph.D. Chief Development Officer | 340.8K | — | — | 2.03M | 73.5K | 1.9K | 2.45M | 82.99% | ↗ |
| 25 | 2019 | Michael Richman President and Chief Executive Officer | 418.5K | — | — | — | 204.0K | 3.1K | 625.7K | 0.00% | ↗ |
| 26 | 2019 | Michael Richman President and Chief Executive Officer | 418.5K | — | — | — | 204.0K | 3.1K | 625.7K | 0.00% | ↗ |
| 27 | 2019 | Kevin Heller, M.D. Former Chief Medical Officer | 369.0K | — | — | — | 133.5K | 2.8K | 505.3K | 0.00% | ↗ |
| 28 | 2019 | Sol Langermann Chief Scientific Officer | 351.6K | — | — | — | 106.0K | 1.5K | 459.1K | 0.00% | ↗ |
| 29 | 2019 | Sol Langermann Chief Scientific Officer | 351.6K | — | — | — | 106.0K | 1.5K | 459.1K | 0.00% | ↗ |
| 30 | 2018 | Michael Richman President and Chief Executive Officer | 383.4K | — | — | 1.96M | 154.5K | 493.00 | 2.50M | 78.48% | ↗ |
| 31 | 2018 | Sol Langermann Chief Scientific Officer | 341.0K | — | — | 455.0K | 85.8K | 493.00 | 882.3K | 51.57% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael S. Richman MSBA | Co-Founder, Chief Executive Officer, President & Director | 752.5K | male |
| Udayan Guha | Chief Medical Officer | 724.5K | — |
| Timothy Mayer | Chief Operating Officer | 560.5K | — |
| Steven Cobourn | Chief Financial Officer | 313.3K | male |
| Sourav Kundu | Senior Vice President of Development & Manufacturing | — | male |
| Lieping Chen | Co-Founder & Chairman of Scientific Advisory Board | — | — |
| Sebastien Maloveste | Senior Vice President of Business Development | — | — |
| Kevin G. Shaw | Senior Vice President & General Counsel | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NXTC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
